<br>        Inclusion Criteria:<br><br>          -  Patients aged 10 to 17 years (inclusive) at the time of randomisation (Visit 2)<br><br>          -  Male and female patients<br><br>          -  Women of childbearing potential (WOCBP) must be ready and able to use highly effective<br>             methods of birth control per ICH M3 (R2) that result in a low failure rate of less<br>             than 1% per year when used consistently and correctly. A list of contraception methods<br>             meeting these criteria is provided in the patient's legal representative information<br>             sheet.<br><br>          -  Signed and dated written informed consent provided by the patient's parent(s) (or<br>             legal guardian) and patient's assent in accordance with ICH-GCP and local legislation<br>             prior to admission to the trial (informed assent will be sought according to the<br>             patient's age, level of maturity, competence and capacity)<br><br>          -  Documented diagnosis of T2DM for at least 12 weeks at Visit 1A<br><br>          -  Insufficient glycaemic control as measured by the central laboratory at Visit 1A:<br><br>               -  DINAMO TM: HbA1c = 6.5% and = 10.5%<br><br>               -  DINAMO TM Mono: HbA1c = 6.5% and = 9.0%<br><br>          -  DINAMO TM: Patients treated with<br><br>               -  diet and exercise plus metformin at a stable dose for 8 weeks prior to Visit 2<br>                  AND/OR<br><br>               -  diet and exercise plus stable basal or MDI insulin therapy,, defined as a weekly<br>                  average variation of the basal insulin dose = 0.1 IU/kg over 8 weeks prior to<br>                  Visit 2. Patients treated with diet and exercise only and not tolerating<br>                  metformin (defined as patients who were on metformin treatment for at least 1<br>                  week and had to discontinue metformin due to metformin-related side effects as<br>                  assessed by the investigator) are also eligible in this trial.<br><br>          -  DINAMOTM Mono: Drug-naïve patients or patients not on active treatment (including a<br>             metformin washout for at least 12 weeks prior to Visit 2)<br><br>          -  BMI = 85th percentile for age and sex according to WHO references at Visit 1B<br><br>          -  Non-fasting serum C-peptide levels = 0.6 ng/ml as measured by the central laboratory<br>             at Visit 1A<br><br>          -  Compliance with trial medication intake must be between 75% and 125% during the<br>             open-label placebo run-in period<br><br>          -  Further inclusion criteria apply<br><br>        Exclusion Criteria:<br><br>          -  Any history of acute metabolic decompensation such as diabetic ketoacidosis within 8<br>             weeks prior to Visit 1A and up to randomisation (mild to moderate polyuria at the time<br>             of randomisation is acceptable)<br><br>          -  Diagnosis of monogenic diabetes (e.g. MODY)<br><br>          -  History of pancreatitis<br><br>          -  Diagnosis of metabolic bone disease<br><br>          -  Gastrointestinal disorders that might interfere with study drug absorption according<br>             to investigator assessment<br><br>          -  Secondary obesity as part of a syndrome (e.g. Prader-Willi syndrome)<br><br>          -  Any antidiabetic medication (with the exception of metformin and/or insulin background<br>             therapy) within 8 weeks prior to Visit 1A and until Visit 2<br><br>          -  Treatment with weight reduction medications (including anti-obesity drugs) within 3<br>             months prior to Visit 1A and until Visit 2<br><br>          -  History of weight-loss surgery or current aggressive diet regimen (according to<br>             investigator assessment) at Visit 1A and until Visit 2<br><br>          -  Treatment with systemic corticosteroids for > 1 week within 4 weeks prior to Visit 1A<br>             and up to Visit 2 Inhaled or topical use of corticosteroids (e.g. for asthma/chronic<br>             obstructive pulmonary disease) is acceptable.<br><br>          -  Change in dose of thyroid hormones within 6 weeks prior to Visit 1A or planned change<br>             or initiation of such therapy before Visit 2<br><br>          -  Known hypersensitivity or allergy to the investigational products or their excipients<br><br>          -  Impaired renal function defined as estimated Glomerular Filtration Rate (eGFR) < 60<br>             ml/min/1.73m² (according to Zappitelli formula) as measured by the central laboratory<br>             at Visit 1A<br><br>          -  Indication of liver disease defined by serum level of either alanine transaminase<br>             (ALT), aspartate transaminase (AST) or alkaline phosphatase above 3 fold upper limit<br>             of normal (ULN) at Visit 1A as measured by the central laboratory at Visit 1A<br><br>          -  History of belonephobia (needle phobia)<br><br>          -  Any documented active or suspected malignancy or history of malignancy within 5 years<br>             prior to Visit 1A, except appropriately treated basal cell carcinoma of the skin or in<br>             situ carcinoma of uterine cervix<br><br>          -  Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells (e.g.<br>             malaria, babesiosis, haemolytic anaemia)<br><br>          -  Any other acute or chronic medical or psychiatric condition or laboratory abnormality<br>             that, based on investigator's judgement, would jeopardize patient safety during trial<br>             participation or would affect the study outcome<br><br>          -  Medical contraindications to metformin according to the local label (for patient on<br>             metformin background therapy)<br><br>          -  Patient not able or cannot be supported by his/her parent(s) or legal guardian to<br>             understand and comply with study requirements based on investigator's judgement<br><br>          -  Previous randomisation in this trial<br><br>          -  Currently enrolled in another investigational device or drug trial, or less than 30<br>             days since ending another investigational device or drug trial(s), or receiving other<br>             investigational treatment(s)<br><br>          -  Chronic alcohol or drug abuse within 3 months prior to Visit 1A or any condition that,<br>             in the investigator's opinion, makes them an unreliable trial patient or unlikely to<br>             complete the trial<br><br>          -  Female patients who are pregnant, nursing, or who plan to become pregnant in the trial<br>